{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:51:08Z","timestamp":1785131468709,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004442","name":"National Science Centre","doi-asserted-by":"crossref","award":["DEC-2013\/11\/B\/NZ7\/02081"],"award-info":[{"award-number":["DEC-2013\/11\/B\/NZ7\/02081"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Funds for Statutory Activity of Jagiellonian University Medical College, Krakow, Poland","award":["K\/ZDS\/005545"],"award-info":[{"award-number":["K\/ZDS\/005545"]}]},{"name":"Funds for Statutory Activity of Jagiellonian University Medical College, Krakow, Poland","award":["K\/ZDS\/007128"],"award-info":[{"award-number":["K\/ZDS\/007128"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.ejphar.2017.12.036","type":"journal-article","created":{"date-parts":[[2017,12,17]],"date-time":"2017-12-17T06:48:08Z","timestamp":1513493288000},"page":"39-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Antiallodynic and antihyperalgesic activity of new 3,3-diphenyl-propionamides with anticonvulsant activity in models of pain in mice"],"prefix":"10.1016","volume":"821","author":[{"given":"Anna","family":"Rapacz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Obniska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Koczurkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"W\u00f3jcik-Pszczo\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Siwek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grybo\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Rybka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Karcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"P\u0119kala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Filipek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.12.036_bib1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1248\/bpb.b13-00735","article-title":"Comparison of the effects of single doses of elcatonin and pregabalin on oxaliplatin-induced cold and mechanical allodynia in rats","volume":"37","author":"Aoki","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2017.12.036_bib2","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1097\/01.j.pain.0000460358.01998.15","article-title":"Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms?","volume":"156","author":"Attal","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.ejphar.2017.12.036_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2006.04.009","article-title":"Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy","volume":"539","author":"Beyreuther","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.12.036_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1527-3458.2007.00001.x","article-title":"Lacosamide: a review of preclinical properties","volume":"13","author":"Beyreuther","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejphar.2017.12.036_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","article-title":"Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms?","volume":"596","author":"Carozzi","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2017.12.036_bib6","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.12.036_bib7","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejphar.2017.12.036_bib8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-200060040-00005","article-title":"Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies","volume":"60","author":"Culy","year":"2000","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ejphar.2017.12.036_bib9","doi-asserted-by":"crossref","first-page":"e0128080","DOI":"10.1371\/journal.pone.0128080","article-title":"Antineuropathic profile of N-palmitoylethanolamine in a rat model of oxaliplatin-induced neurotoxicity","volume":"10","author":"Di Cesare Mannelli","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2017.12.036_bib10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2174\/138920010794233503","article-title":"Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution","volume":"11","author":"Emoto","year":"2010","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejphar.2017.12.036_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/138920012798918426","article-title":"Liver-based in vitro technologies for drug biotransformation studies \u2013 a review","volume":"13","author":"Fasinu","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejphar.2017.12.036_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2017.12.036_bib13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1248\/bpb.32.732","article-title":"Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit","volume":"32","author":"Gauchan","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejphar.2017.12.036_bib14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.neuropharm.2011.05.001","article-title":"Lacosamide has protective disease modifying properties in experimental vincristine neuropathy","volume":"61","author":"Geis","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2017.12.036_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/14728214.2014.915025","article-title":"Emerging drugs for neuropathic pain","volume":"19","author":"Gilron","year":"2014","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejphar.2017.12.036_bib16","doi-asserted-by":"crossref","first-page":"350","DOI":"10.11607\/ofph.1317","article-title":"Pregabalin reduces acute inflammatory and persistent pain associated with nerve injury and cancer in rat models of orofacial pain","volume":"28","author":"Hummig","year":"2014","journal-title":"J. Oral. Facial Pain. Headache"},{"key":"10.1016\/j.ejphar.2017.12.036_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharep.2014.08.013","article-title":"The antinociceptive effect and mechanisms of action of pregabalin in mice","volume":"67","author":"Kaygisiz","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2017.12.036_bib18","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2147\/JPR.S141896","article-title":"Phenytoin and carbamazepine in trigeminal neuralgia: marketing-based versus evidence-based treatment","volume":"10","author":"Keppel Hesselink","year":"2017","journal-title":"J. Pain. Res."},{"key":"10.1016\/j.ejphar.2017.12.036_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13181-017-0626-4","article-title":"The pharmacology and toxicology of third-generation anticonvulsant drugs","volume":"13","author":"LaPenna","year":"2017","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.ejphar.2017.12.036_bib20","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1124\/jpet.302.3.1168","article-title":"Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception","volume":"302","author":"Laughlin","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2017.12.036_bib21","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.neuropharm.2008.06.007","article-title":"Comparative antiallodynic activity of morphine, pregabalin and lidocaine in a rat model of neuropathic pain produced by one oxaliplatin injection","volume":"55","author":"Ling","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2017.12.036_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1871527311312010009","article-title":"Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial\/microglial phenotypical changes in mice","volume":"12","author":"Luongo","year":"2013","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.ejphar.2017.12.036_bib23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s11920-012-0302-y","article-title":"What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia?","volume":"14","author":"McCall","year":"2012","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.ejphar.2017.12.036_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2013.01.072","article-title":"Importance of glial activation in neuropathic pain","volume":"716","author":"Mika","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.12.036_bib25","first-page":"350","article-title":"Synthesis and anticonvulsant properties of new 3,3-diphenyl-2,5-dioxo-pyrrolidin-1-yl-acetamides and 3,3-diphenyl-propionamides","author":"Obniska","year":"2017","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.ejphar.2017.12.036_bib26","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.nurt.2009.07.004","article-title":"Diabetic painful and insensate neuropathy: pathogenesis and potential treatments","volume":"6","author":"Obrosova","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejphar.2017.12.036_bib27","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2009.04.007","article-title":"Treatment of neuropathic pain: an overview of recent guidelines","volume":"122","author":"O'Connor","year":"2009","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejphar.2017.12.036_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejphar.2016.04.033","article-title":"Anticonvulsant and antinociceptive activity of new amides derived from 3-phenyl-2,5-dioxo-pyrrolidine-1-yl-acetic acid in mice","volume":"781","author":"Rapacz","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.12.036_bib29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00210-015-1194-2","article-title":"Evaluation of anticonvulsant and antinociceptive properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and 3-methylpyrrolidine-2,5-dione","volume":"389","author":"Rapacz","year":"2016","journal-title":"Naunyn Schmiede. Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.12.036_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00210-017-1358-3","article-title":"Analgesic, antiallodynic, and anticonvulsant activity of novel hybrid molecules derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide in animal models of pain and epilepsy","volume":"390","author":"Rapacz","year":"2017","journal-title":"Naunyn Schmiede. Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.12.036_bib31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1039\/C6MD00537C","article-title":"Design, synthesis and anticonvulsant-analgesic activity of new N-[(phenoxy)alkyl]- and N-[(phenoxy)ethoxyethyl]aminoalkanols","volume":"8","author":"Rapacz","year":"2017","journal-title":"Med. Chem. Comm."},{"key":"10.1016\/j.ejphar.2017.12.036_bib32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/01.ajp.0000210957.39621.b2","article-title":"Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study","volume":"23","author":"Rauck","year":"2007","journal-title":"Clin. J. Pain."},{"key":"10.1016\/j.ejphar.2017.12.036_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00210-013-0847-2","article-title":"Evaluation of antinociceptive and antioxidant properties of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one in mice","volume":"386","author":"Sa\u0142at","year":"2013","journal-title":"Naunyn Schmiede. Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.12.036_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.pbb.2014.03.025","article-title":"Antiallodynic and antihyperalgesic activity of 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one compared to pregabalin in chemotherapy-induced neuropathic pain in mice","volume":"122","author":"Sa\u0142at","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2017.12.036_bib35","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jpain.2009.01.322","article-title":"Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial","volume":"10","author":"Shaibani","year":"2009","journal-title":"J. Pain."},{"key":"10.1016\/j.ejphar.2017.12.036_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4172\/2157-7609.1000126","article-title":"Comparative in-vitro intrinsic clearance of imipramine in multiple species liver microsomes: human, rat, mouse and dog","volume":"3","author":"Singh","year":"2012","journal-title":"J. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejphar.2017.12.036_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jdi.12379","article-title":"Microglia in the spinal cord and neuropathic pain","volume":"7","author":"Tsuda","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.ejphar.2017.12.036_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pbb.2015.05.007","article-title":"Antinociceptive and hypnotic activities of pregabalin in a neuropathic pain-like model in mice","volume":"135","author":"Wang","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2017.12.036_bib39","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ejpain.2008.09.010","article-title":"Gabapentin reverses microglial activation in the spinal cord of streptozotocin-induced diabetic rats","volume":"13","author":"Wodarski","year":"2009","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.ejphar.2017.12.036_bib40","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jpain.2006.11.007","article-title":"Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats","volume":"8","author":"Yokoyama","year":"2007","journal-title":"J. Pain"},{"key":"10.1016\/j.ejphar.2017.12.036_bib41","doi-asserted-by":"crossref","first-page":"33853","DOI":"10.1074\/jbc.M112.395830","article-title":"N-methyl-D-aspartate receptor- and calpain-mediated proteolytic cleavage of K+-Cl- cotransporter-2 impairs spinal chloride homeostasis in neuropathic pain","volume":"287","author":"Zhou","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2017.12.036_bib42","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2337\/dc09-1578","article-title":"Lacosamide SP743 Study Group. Efficacy and safety of lacosamide in painful diabetic neuropathy","volume":"33","author":"Ziegler","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2017.12.036_bib43","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S1734-1140(13)71521-4","article-title":"Mechanisms and pharmacology of diabetic neuropathy \u2013 experimental and clinical studies","volume":"65","author":"Zychowska","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejphar.2017.12.036_bib44","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/ALN.0000000000001219","article-title":"Microglial inhibition influences XCL1\/XCR1 expression and causes analgesic effects in a mouse model of diabetic neuropathy","volume":"125","author":"Zychowska","year":"2016","journal-title":"Anesthesiology"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917308312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917308312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T18:46:10Z","timestamp":1589827570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917308312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":44,"alternative-id":["S0014299917308312"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.12.036","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiallodynic and antihyperalgesic activity of new 3,3-diphenyl-propionamides with anticonvulsant activity in models of pain in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.12.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}